LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Bespak – 21.05.2025
Stoelzle – 15th May 2025

Regulatory Trends and Developments in the Pharmaceutical Industry in 2018

In the 2017 fiscal year, the FDA issued 114 warning letters to pharmaceutical manufacturers contravening Current Good Manufacturing practices (cGMPs). This followed a trend of continual increase in warning letters, with 102 issued in FY2016 and 42 issued in FY2015. Though this rise suggests that pharmaceutical companies are slacking in the field of
compliance, it is more likely to be a reflection of increased scrutiny within the FDA and of evolving areas of focus. In this article, Jennifer Lopez from Maetrics explores why this is the case, and looks at lessons learnt from this increased scrutiny.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
L.B. Bohle – 08.04.2025